News & Updates

There is no apparent increased risk of deep vein thrombosis (DVT) following receipt of the COVID-19 vaccine, according to a study presented at ASH 2021.

In the treatment of patients with COVID-19, administering remdesivir within 5 days of symptom onset appears to reduce the risk of progression to severe disease, as shown in a study.

In the phase II proof-of-concept CATALYST trial comparing the GM-CSF* inhibitor namilumab and the TNF** inhibitor infliximab against usual care (UC), namilumab, but not infliximab, demonstrated signals for reducing inflammation in hospitalized patients with COVID-19 pneumonia.

A weak innate immunity appears to play a central role in severe infections of the coronavirus disease 2019 (COVID-19), a recent study has found.

Treatment with the selective serotonin reuptake inhibitor fluvoxamine may prevent hospitalization in outpatients presenting with symptoms of COVID-19 who have a high risk for disease progression, according to results of the TOGETHER trial.

Use of atorvastatin in adults with COVID-19 admitted to the intensive care unit (ICU) is safe but does not result in a marked decrease in the composite of venous or arterial thrombosis, treatment with extracorporeal membrane oxygenation, or all-cause mortality, a study has shown.

Vaccines against the coronavirus disease 2019 (COVID-19) often cause temporary disturbances in cardiovascular, respiratory, and sleep physiology, according to a new study. Moreover, such perturbations can be detected by wearable devices.

Bacteraemic pneumococcal community-acquired pneumonia is associated with higher disease severity and frequent intensive care unit admission, as reported in a study. However, SARS-CoV-2-related pneumonia poses a greater mortality risk.